Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 하정미 | - |
dc.date.accessioned | 2019-11-19T06:33:30Z | - |
dc.date.available | 2019-11-19T06:33:30Z | - |
dc.date.issued | 2019-02 | - |
dc.identifier.citation | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, v. 163, Page. 453-480 | en_US |
dc.identifier.issn | 0223-5234 | - |
dc.identifier.issn | 1768-3254 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0223523418309966 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/112371 | - |
dc.description.abstract | Here we first time report an unprecedented and unnatural six-membered 1,5-oxaza spiroquinone scaffold with structural novelty, a convenient and efficient synthetic route was developed for the synthesis of new 1,5-oxaza spiroquinone derivatives (1a-1r) in high yields from readily available starting materials. The logic of the present work consists of (1) the identification of a promising unprecedented scaffold from privileged scaffolds of biological active molecules through our 'Chemistry-oriented Synthesis' (ChOS) approach, a compensatory strategy for target-based drug discovery, (2) the positioning of the identified 1,5-oxaza spiroquinone scaffold on neuroinflammation and neurodegenerative disease through nitric oxide (NO) inhibitory activity without cytotoxicity in hyper-activated microglia (IC50 of NO production: 0.07-1.82 mu M) to establish structure-activity relationship (SAR), (3) the investigation on the possibility as a selective kinase inhibitor related to neurodegenerative diseases (eg. JNK1, CDK2, DAPK1) through kinase full panel screening of the most potent compound 1n, and (4) the evaluation on in vivo efficacy of the compound 1n through Y-maze test. (C) 2018 Elsevier Masson SAS. All rights reserved. | en_US |
dc.description.sponsorship | This study was supported by the Basic Science Research Program of the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science, and Technology (No.: 2017R1E1A1A01076642). In addition, a grant was also provided by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry for Health and Welfare, Korea (No.: HI14C1135). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER | en_US |
dc.subject | 1,5-oxaza spiroquinone | en_US |
dc.subject | Chemistry-oriented synthesis | en_US |
dc.subject | Neurodegenerative | en_US |
dc.subject | NO inhibitory effect | en_US |
dc.subject | JNK | en_US |
dc.subject | DAPK | en_US |
dc.subject | Molecular docking simulation | en_US |
dc.subject | Y-maze test | en_US |
dc.title | Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone | en_US |
dc.type | Article | en_US |
dc.relation.volume | 163 | - |
dc.identifier.doi | 10.1016/j.ejmech.2018.11.037 | - |
dc.relation.page | 453-480 | - |
dc.relation.journal | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | - |
dc.contributor.googleauthor | Venkanna, Arramshetti | - |
dc.contributor.googleauthor | Cho, Kyo Hee | - |
dc.contributor.googleauthor | Dhorma, Lama Prema | - |
dc.contributor.googleauthor | Kumar, Duddukuri Nandan | - |
dc.contributor.googleauthor | Hah, Jung Mi | - |
dc.contributor.googleauthor | Park, Hyeung-geun | - |
dc.contributor.googleauthor | Kim, Sun Yeou | - |
dc.contributor.googleauthor | Kim, Mi-hyun | - |
dc.relation.code | 2019001547 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | jhah | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.